Molecular Atlas of HER2+ Breast Cancer Cells Treated with Endogenous Ligands: Temporal Insights into Mechanisms of Trastuzumab Resistance

• Published in: Cancers 2024-01, Vol.16 (3), p.553
• Main Authors: Mukund, Kavitha, Alva-Ornelas, Jackelyn A, Maddox, Adam L, Murali, Divya, Veraksa, Darya, Saftics, Andras, Tomsic, Jerneja, Frankhouser, David, Razo, Meagan, Jovanovic-Talisman, Tijana, Seewaldt, Victoria L, Subramaniam, Shankar
• Format: Article
• Language: English
• Subjects: 1-Phosphatidylinositol 3-kinase; AKT protein; Antibodies; Bioenergetics; Breast cancer; Cancer cells; Cancer therapies; Care and treatment; Cell culture; Cellular stress response; Chromatin; Data analysis; Epidermal growth factor; ErbB-2 protein; Experiments; Heregulin; Interferon regulatory factor 1; Kinases; Ligands; Lipid metabolism; Localization; Microscopy; Mutation; Phenols; Physiological aspects; Proteins; Stat1 protein; Trastuzumab
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16030553

Trastuzumab therapy in HER2+ breast cancer patients has mixed success owing to acquired resistance to therapy. A detailed understanding of downstream molecular cascades resulting from trastuzumab resistance is yet to emerge. In this study, we investigate the cellular mechanisms underlying acquired resistance using trastuzumab-sensitive and -resistant cancer cells (BT474 and BT474R) treated with endogenous ligands EGF and HRG across time. We probe early receptor organization through microscopy and signaling events through multiomics measurements and assess the bioenergetic state through mitochondrial measurements. Integrative analyses of our measurements reveal significant alterations in EGF-treated BT474 HER2 membrane dynamics and robust downstream activation of PI3K/AKT/mTORC1 signaling. EGF-treated BT474R shows a sustained interferon-independent activation of the IRF1/STAT1 cascade, potentially contributing to trastuzumab resistance. Both cell lines exhibit temporally divergent metabolic demands and HIF1A-mediated stress responses. BT474R demonstrates inherently increased mitochondrial activity. HRG treatment in BT474R leads to a pronounced reduction in AR expression, affecting downstream lipid metabolism with implications for treatment response. Our results provide novel insights into mechanistic changes underlying ligand treatment in BT474 and BT474R and emphasize the pivotal role of endogenous ligands. These results can serve as a framework for furthering the understanding of trastuzumab resistance, with therapeutic implications for women with acquired resistance.